National and Kapodistrian University of Athens
Εκτίμηση της μεταβολής της ελαστικότητας των μεγάλων αρτηριών μετά από χορήγηση αντι- TNF παραγόντων σε ασθενείς με ρευματοειδή αρθρίτιδα: συγκριτική μελέτη
Abstract
dc:descriptionBackground: Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory disease, which is associated with increased cardiovascular mortality. Aortic stiffness is an independent marker and prognosticator of cardiovascular risk. Aim of the study: We investigated whether there is an effect of treatment with the TNF antagonist adalimumab on aortic stiffness in RA patients and whether that effect is independent of the response to treatment. Furthermore, we examined whether there is a differential effect on aortic stiffness among patients treated with a classic disease modifying anti-rheumatic drug (DMARD) i.e. methotrexate. Methods: A total of 130 patients were included in the study but finally we studied 36 RA patients (age 60.08 ± 11.92 yrs) with active disease (disease duration 6.22 ± 6.16 yrs), who received either adalimumab (± DMARDs, n = 18) or methotrexate (n=18) for 12 weeks. All patients underwent evaluation of clinical status and inflammatory markers such as CRP and ESR, at baseline and at the end of treatment period. DAS 28 score was used an inidicator of RA disease activity. Carotid-femoral Pulse Wave Velocity (PWV) was measured as an index of aortic stiffness. Τhe group that received adalimumab was further divided into two subgroups according to the response to treatment (DAS28 decrease > or < 1.2). The changes in measures of disease activity, aortic stiffness and inflammatory state from baseline to 12 weeks were compared between the groups and subgroups.Results: PWV decreased in patients that received adalimumab over 12 weeks (from 8.2±2 to 7.0±1.8 m/s, P<0.05) in comparison to methotrexate (from 8.9±1.9 to 8.4±2.2 m/s, P=NS). In addition, compared to baseline, a significant decrease in DAS 28 was found both at 12 weeks after treatment with adalimumab and methotrexate. The favorable effect of adalimumab on aortic stiffness was sustained, unlike the response to treatment (from 8.0±2.0 to 6.9±1.9 m/s, P<0.05 for the non-responders and from 8.3±2.1 m/s to 7.0±1.8 m/s, P<0.05 for the responders). Finally a net decrease was found in A.Ix (Augmentation index), in ESR and CRP in both groups.Conclusions: With regard to aortic stiffness, adalimumab treatment resulted in significantly greater decrease in carotid-femoral PWV over the follow up period of 12-weeks, than treatment with methotrexate. This favorable effect of adalimumab was independent of its effect on RA disease activity. This finding may have important implications in the long term cardiovascular risk in RA patients treated with anti-TNF agents.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2014
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Gravos, Athanasios
- Γράβος, Αθανάσιος
Subjects
dc:subject × 10Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/41847